Dr. Matthew T. Whitehurst, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Maryland School of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 1,412
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: University of Maryland School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
VA license 0101257665 -
Hematology (Internal Medicine) Physician
VA license 0101257665 -
Internal Medicine Physician
FL license ME113141 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mary Washington Hospital Fredericksburg, VA
- Uva Health Culpeper Medical Center Culpeper, VA
- Stafford Hospital, LLC Stafford, VA
- Spotsylvania Regional Medical Center Fredericksburg, VA
Medical groups
- American Oncology PArtners PA (391 clinicians)
- Hematology-Oncology Associates of Fredericksburg Inc (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,412
- Services billed
- 390,326
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 42,750 | 50 |
| Injection, denosumab, 1 mg | 16,380 | 113 |
| Injection, nivolumab, 1 mg | 14,825 | 18 |
| Injection, pembrolizumab, 1 mg | 14,600 | 25 |
| Injection, aprepitant, 1 mg | 11,830 | 36 |
| Injection, paclitaxel, 1 mg | 5,920 | 13 |
| Injection, fosaprepitant, 1 mg | 5,100 | 11 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 3,520 | 41 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 3,460 | 22 |
| Injection, dexamethasone sodium phosphate, 1 mg | 3,328 | 95 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Fredericksburg, VA | 164 |
| Anastrozole Other prescribers in Fredericksburg, VA | 103 |
| Xarelto (rivaroxaban) Other prescribers in Fredericksburg, VA | 57 |
| Famotidine Other prescribers in Fredericksburg, VA | 53 |
| Prednisone Other prescribers in Fredericksburg, VA | 45 |
| Exemestane | 43 |
| Hydroxyurea Other prescribers in Fredericksburg, VA | 39 |
| Ondansetron Hcl Other prescribers in Fredericksburg, VA | 33 |
| Potassium Chloride Other prescribers in Fredericksburg, VA | 31 |
| Pantoprazole Sodium Other prescribers in Fredericksburg, VA | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 88 payments worth $2,823 in total to this clinician.
| Food and Beverage | $1,943 |
|---|---|
| Consulting Fee | $860 |
| Education | $20.51 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Jun 10, 2025 | Consulting Fee | $860 |
| Janssen Pharmaceuticals, Inc Oct 2, 2025 | Education in-kind | $20.51 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $90,051 in research payments for these studies, mostly to the institutions running them.
- A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Partner Therapeutics, Inc. - A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib …
Merck Sharp & Dohme LLC - Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Mirati Therapeutics, Inc. · Active, not recruiting · NCT04793958
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.